Perspective Therapeutics Inc Dossier - Source-backed chat

Perspective Therapeutics Inc

CATXNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $310.5M

Enterprise Value $263.6M

Shares Outstanding 112.7M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Perspective Therapeutics is a clinical-stage radiopharmaceutical pioneer developing targeted alpha-particle therapies using Lead-212 (212Pb). The company's proprietary platform optimizes tumor targeting, safety, and supply scalability. With three clinical-stage programs (VMT-α-NET, VMT01, and PSV359) and a vertically integrated regional manufacturing network, Perspective is well-positioned to capture a significant share of the rapidly growing radiopharmaceutical market. A strong cash position of $271 million as of Q1 2026 provides a runway into late 2027, mitigating near-term dilution risks while advancing lead programs toward pivotal readouts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$12.64

High · most bullish analyst$18.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.0015%

Clinical trials experience delays in patient enrollment or encounter unexpected safety signals (e.g., dose-limiting toxicities). Regulatory feedback requires larger, more expensive trials, accelerating cash burn. Competitors with alternative radiopharmaceutical platforms gain market share, or construction delays occur at the Chicago manufacturing site.

Base CaseCentral scenario

$12.9360%

Perspective continues steady enrollment and dose-escalation across its three clinical programs, with VMT-α-NET meeting its follow-up milestones by late 2026. Regulatory feedback confirms a clear path to a registrational trial. Manufacturing expansion progresses as planned, and the cash runway remains sufficient into late 2027, supporting steady valuation appreciation toward consensus targets.

Bull CaseUpside scenario

$18.0025%

Lead candidate VMT-α-NET demonstrates exceptional efficacy and safety in SSTR2-positive neuroendocrine tumors, leading to rapid FDA alignment on a registration-enabling study. Concurrently, VMT01 (melanoma) and PSV359 (FAP-α solid tumors) show strong early efficacy, attracting high-value pharmaceutical partnerships. The Chicago manufacturing facility is completed ahead of schedule, securing a robust supply chain.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Lead-212 (212Pb) alpha-emitting platform offering superior tumor-killing potency compared to traditional beta-emitters.
Robust clinical pipeline with three active clinical-stage programs targeting high-value oncology indications.
Strong financial position with $271 million in cash as of March 31, 2026, providing a runway into late 2027.
Vertically integrated regional manufacturing network designed to address the industry's critical isotope supply and distribution challenges.

Key Investment Risks

Clinical development risk inherent to early-stage (Phase 1/2a) oncology trials.
Dependence on regulatory approvals and alignment for registration-enabling studies.
Intense competition within the radiopharmaceutical space from both established pharma and emerging biotech players.
Long-term capital requirements to fund commercialization and pipeline expansion beyond the current cash runway.

Thesis Invalidation Triggers

Failure to align with the FDA on a registration-enabling study design for VMT-α-NET in 2026.
Emergence of severe, unexpected treatment-related adverse events in ongoing clinical trials.
Significant delays or cost overruns in the construction and validation of the Chicago manufacturing facility.
A material acceleration in cash burn rate that shortens the projected runway to mid-2027 or earlier.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.